The guideline summarized in this manuscript has been endorsed by the Multi-National Association for Supportive Care in Cancer and the C17 Research Network.
Clinical Practice Guideline
Version of Record online: 19 MAR 2013
Copyright © 2013 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 7, pages 1073–1082, July 2013
How to Cite
Dupuis, L. L., Boodhan, S., Holdsworth, M., Robinson, P. D., Hain, R., Portwine, C., O'Shaughnessy, E. and Sung, L. (2013), Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr. Blood Cancer, 60: 1073–1082. doi: 10.1002/pbc.24508
Conflict of interest: Nothing to declare.
- Issue online: 22 MAY 2013
- Version of Record online: 19 MAR 2013
- Manuscript Accepted: 29 JAN 2013
- Manuscript Received: 11 SEP 2012
- Pediatric Oncology Group of Ontario
- Ministry of Health and Long Term Care, Ontario
- Children's Oncology Group
- 3An evaluation of the implementation of the MASCC anti-emetic guideline for anthracycline-cyclophosphamide based chemotherapy in female patients [abstract]. Support Care Cancer 2010;18:S82–S83..
- 5Guideline for classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients, 2010. (Accessed November 11, 2012, at http://www.pogo.ca/healthcare/practiceguidelines/).
- 6Guideline for the Prevention of Acute Nausea, Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients, 2012. (Accessed November 11, 2012, at http://www.pogo.ca/healthcare/practiceguidelines/).
- 7The ADAPTE Collaboration. (Accessed January 20, 2009, at http://www.adapte.org/ .).
- 8CAN-IMPLEMENT©: A Guideline Adaptation and Implementation Planning Resource, 2011. Queen's University School of Nursing and Canadian Partnership Against Cancer, 2011. (Accessed June 30, 2011, at http://www.cancerview.ca/idc/groups/public/documents/webcontent/can_implement_guide_lines.pdf).
- 17The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multi-national, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112–4119. Pregent, E. Merck Frosst Canada Ltd, Personal communication to L. L. Dupuis March 14, 2007., , , et al.
- 18Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2010; 1–87. Art. No.: CD007786. DOI: 10.1002/14651858.CD007786.pub2, , , et al.
- 19A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatr Hematol Oncol 2000;17:445–455., , , et al.
- 21Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated withantineoplastic chemotherapy: A prospective randomized study. Eur J Pediatr 1998;157:806–810., , , et al.
- 30Utilisation de l'aprepitant pour les nauseea et les vomissements regractaries secondaires a la chimiotherapie chez une adolescente. Pharmactuel 2005;38:220–225., .
- 32Effect of aprepitant on antiemetic protection in adolescents with cancer receiving highly emetogenic chemotherapy: A preliminary experience [abstract]. Support Care Cancer 2005;13:422., , , et al.
- 33Use of aprepitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients [abstract]. J Pediatr Pharmacol Ther 2008;13:191., , , et al.
- 38Dexamethasone as an antiemetic in children receiving cis-platinum. Am J Pediatr Hematol Oncol 1988;10:126–128., , , et al.
- 42A controlled, dose-comparison study of granisetron for nausea and vomiting induced by cancer chemotherapy in children. Int J Clin Oncol 1996;1:57–60., , , et al.
- 60Drug FDA Communication: Safety New information regarding QT prolongation with ondansetron (Zofran), June 29, 2012. (Accessed August 27, 2012, at http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm).